Skip to main content

KALY – Kali-Extracts Announces Getting Courted For Potential Sale Of Cannabis Extract Biopharmaceutical Technology

Written by Customer Service on . Posted in Public Companies.

DALLAS, Oct. 23, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced the company has recently received serious interest from an investor exploring the acquisition of KALY’s Cannabis Extract Biopharmaceutical Technology.  KALY CEO Frederick Ferri commented on the acquisition interest in KALY’s Cannabis Extract Biopharmaceutical Technology indicating that the interest stems from industry investors recognizing that KALY’s technology is undervalued.
In the fourth quarter of last year, 2018, KALY acquired NCMB.  NCMB owns and operates a US Patented Cannabis Extraction Process.  In NCMB’s four years of operations prior to the acquisition by KALY, NCMB established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process.  The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY now has a deep pipeline of cannabinoid product candidates including four distinct compounds listed here: 
Chronic Obstructive Pulmonary Disease (COPD) – The market for COPD treatment is anticipated to reach $14 billion by 2025;
Type 2 Diabetes – The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;
Cancer Pain Management – The overall pain management treatment market is anticipated to reach $83 billion by 2024, and
Epilepsy – The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
In conjunction with the research already conducted and the next phase of research now moving forward, KALY recently filed for a new patent application specifically on its formulation for symptoms associated with COPD and other similar respiratory conditions.  KALY also filed for a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions.  The market for COPD treatment is anticipated to reach $14 billion by 2025. In addition to KALY’s ongoing efforts to develop prescription therapies, KALY has initiated a program to certify its proprietary CBD extracts derived from KALY’s U.S. Patented Extraction Process as an Over-The-Counter (OTC) drug under the requirements prescribed by the U.S. Food and Drug Administration.  Since the last biopharmaceuticals strategy update, KALY has made substantial strides.  KALY has since engaged with a major university to initiate a next round of evaluations and testing of its COPD treatment.  The university program is anticipated to kickoff soon and the company plans to issue periodic updates as the program proceeds. KALY has also made recent progress in advancing the development of its other treatments.  The advances have been made possible by new partnerships.  Announcements about the new partnerships are coming soon.KALY has implemented a sustainable strategy to develop cannabis extracts from its US Patented Cannabis Extraction Process to treat a variety of specific health issues.  In light of the long-term commitment to the biopharmaceutical development process and the corresponding requirement for continuous fund raising through the process, KALY has implemented a parallel business strategy to more immediately monetize its patented intellectual property through consumer applications of its technology.  KALY has issued a limited license of its patented process to Puration, Inc. ((USOTC: PURA) for the infusion of cannabis extracts into beverages.  KALY has also developed and is selling its own line of CBD infused candies under the brand name Hemp4mula.  The candies are for sale on North American Cannabis Holdings (USOTC: USMJ) eCommerce site, www.usmj.com.  KALY has also signed direct cannabis extraction contracts with hemp farming operations with a total value so far of $15 million.  KALY management recently announced an anticipated jump in revenue in Q4 2019 related to the company’s CBD extraction contracts with hemp farming operations currently underway now that the hemp harvest season is in full swing. Ferri plans to keep shareholders update regularly on the current interest expressed in the possible acquisition of KALY’s Cannabis Biopharmaceutical Extract Technology.To stay abreast of the latest developments and learn more about the company visit  https://www.kali-extracts.com/.This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.